{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Corpus+Leiomyosarcoma&page=2",
    "query": {
      "condition": "Uterine Corpus Leiomyosarcoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Uterine+Corpus+Leiomyosarcoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:29:14.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01533207",
      "title": "Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stage I Uterine Sarcoma AJCC v7",
        "Uterine Corpus Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2012-06-04",
      "completion_date": "2019-02-09",
      "has_results": true,
      "last_update_posted_date": "2020-04-28",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 608,
      "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 374 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01533207"
    },
    {
      "nct_id": "NCT07076186",
      "title": "Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Trabectedin",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2025-10-02",
      "completion_date": "2029-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07076186"
    },
    {
      "nct_id": "NCT02601209",
      "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High Grade Sarcoma",
        "Metastatic Leiomyosarcoma",
        "Metastatic Malignant Peripheral Nerve Sheath Tumor",
        "Metastatic Synovial Sarcoma",
        "Metastatic Undifferentiated Pleomorphic Sarcoma",
        "Metastatic Unresectable Sarcoma",
        "Myxofibrosarcoma",
        "Recurrent Leiomyosarcoma",
        "Recurrent Malignant Peripheral Nerve Sheath Tumor",
        "Recurrent Synovial Sarcoma",
        "Recurrent Undifferentiated Pleomorphic Sarcoma",
        "Stage III Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8",
        "Unresectable Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Pazopanib",
          "type": "DRUG"
        },
        {
          "name": "Pazopanib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2015-11-30",
      "completion_date": "2022-07-11",
      "has_results": true,
      "last_update_posted_date": "2022-08-23",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 460,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601209"
    },
    {
      "nct_id": "NCT05649956",
      "title": "Letrozole in Uterine Leiomyosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Uterine Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Letrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GOG Foundation",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2024-07-17",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 25,
      "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Fort Lauderdale, Florida + 18 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Highlands Ranch",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05649956"
    },
    {
      "nct_id": "NCT01958580",
      "title": "Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stage IA Uterine Sarcoma",
        "Stage IB Uterine Sarcoma",
        "Stage IC Uterine Sarcoma",
        "Stage IIA Uterine Sarcoma",
        "Stage IIB Uterine Sarcoma",
        "Stage IIIA Uterine Sarcoma",
        "Stage IIIB Uterine Sarcoma",
        "Stage IIIC Uterine Sarcoma",
        "Stage IVA Uterine Sarcoma",
        "Stage IVB Uterine Sarcoma",
        "Uterine Corpus Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Internal Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2013-09-17",
      "completion_date": "2017-02-24",
      "has_results": true,
      "last_update_posted_date": "2023-08-16",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01958580"
    },
    {
      "nct_id": "NCT00101127",
      "title": "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2003-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-02-14",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 60,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • New Britain, Connecticut + 47 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101127"
    },
    {
      "nct_id": "NCT00245102",
      "title": "Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Angiosarcoma",
        "Adult Epithelioid Sarcoma",
        "Adult Leiomyosarcoma",
        "Adult Malignant Fibrous Histiocytoma",
        "Adult Neurofibrosarcoma",
        "Adult Synovial Sarcoma",
        "Ovarian Sarcoma",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Uterine Sarcoma",
        "Stage III Adult Soft Tissue Sarcoma",
        "Stage III Uterine Sarcoma",
        "Stage IV Adult Soft Tissue Sarcoma",
        "Stage IV Uterine Sarcoma",
        "Uterine Carcinosarcoma",
        "Uterine Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 147,
      "start_date": "2005-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2014-05-23",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00245102"
    },
    {
      "nct_id": "NCT00474994",
      "title": "Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Malignant Fibrous Histiocytoma of Bone",
        "Desmoid Tumor",
        "Endometrial Cancer",
        "Ovarian Cancer",
        "Sarcoma",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 53,
      "start_date": "2007-04",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474994"
    },
    {
      "nct_id": "NCT03880019",
      "title": "A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Uterine Corpus Leiomyosarcoma AJCC v8",
        "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8",
        "Uterine Corpus Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Core Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 23,
      "start_date": "2019-08-19",
      "completion_date": "2026-11-12",
      "has_results": true,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03880019"
    },
    {
      "nct_id": "NCT00005643",
      "title": "Chemotherapy in Treating Patients With Sarcoma of the Uterus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "pegylated liposomal doxorubicin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "21 Years and older · Female only"
      },
      "enrollment_count": null,
      "start_date": "2000-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-10",
      "last_synced_at": "2026-05-21T23:29:14.004Z",
      "location_count": 48,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Gatos",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005643"
    }
  ]
}